The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Zhilin Long - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst
: So I guess a follow-up to the EnlivenHealth questions. I'm wondering if you guys can talk about how big is the retail pharmacy business as the
percentage of your total revenue right now? And then as we think about the guidance and as you continue to add more features to the platform,
I guess, what growth assumptions are you -- do you have or what the growth assumption is embedded in the guidance?
Question: Zhilin Long - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst
: Okay. Got it. And then the pricing model there, is it just subscription model based on the number of modules? Is that the right way to think about
it?
Question: Zhilin Long - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst
: Okay. Great. And the other question...
Question: Zhilin Long - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst
: Okay. Great. And then the other question I had is on Omnicell One, it seems that you guys are seeing strong customer interest. So I'm wondering
if you can compare Omnicell One to maybe some of the other software solutions on the market, what's Omnicell One advantage? And then, I guess,
the same similar question there. Can you remind us what's your pricing model and the pricing strategy going forward?
Question: Zhilin Long - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst
: Great. If I may add one more question. So you guys talked a lot about competitive conversion. So I'm wondering what do you think is the main
driver for success there? And then how have that changed maybe compared to last year?
| 
